Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
Friendship Day is a day dedicated to honoring one of the most important relationships in…
The Pithora painting of Gujarat, an ancient wall painting practice of the Rathwa tribe of…
Air Marshal A K Bharti, being one of Indian Air Force's top officers and the…
On 01st of August 2026, Prime Minister Narendra Modi inaugurated the Alluri Sitarama Raju International…
According to the monthly GST revenue report released by the government, the total GST collections…
The Indian athlete Tejaswin Shankar has created the history as he became the first Indian…